Safety Outcomes During Pediatric GH Therapy: Final Results From the Prospective GeNeSIS Observational Program.

导出 OA

翻译打印收藏纠错

作者： Christopher J,Child ^[1] ; Alan G,Zimmermann ^[2] ; George P,Chrousos ^[3] ; Elisabeth,Cummings ^[4] ; Cheri L,Deal ^[5] ; Tomonobu,Hasegawa ^[6] ; Nan,Jia ^[2] ; Sarah,Lawrence ^[7] ; Agnès,Linglart ^[8] ; Sandro,Loche ^[9] ; Mohamad,Maghnie ^[10] ; Jacobo,Pérez Sánchez ^[11] ; Michel,Polak ^[12] ; Barbara,Predieri ^[13] ; Annette,Richter-Unruh ^[14] ; Ron G,Rosenfeld ^[15] ; Diego,Yeste ^[16] ; Tohru,Yorifuji ^[17] ; Werner F,Blum ^[18]

作者单位： Eli Lilly and Company, Windlesham, Surrey, United Kingdom. ^[1] Eli Lilly and Company, Indianapolis, Indiana. ^[2] National and Kapodistrian University of Athens, School of Medicine, Athens, Greece. ^[3] Dalhousie University/IWK Health Centre, Halifax, Nova Scotia, Canada. ^[4] University of Montreal and CHU Ste-Justine, Montreal, Quebec, Canada. ^[5] Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan. ^[6] Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada. ^[7] Hôpital Bicêtre Paris Sud, Paris, France. ^[8] Ospedale Pediatrico Microcitemico "A. Cao," AO Brotzu, Cagliari, Italy. ^[9] Istituto Giannina Gaslini, University of Genova, Genoa, Italy. ^[10] Corporació Sanitària Parc Taulí, Sabadell, Spain. ^[11] Hôpital Universitaire Necker Enfants Malades and Université Paris Descartes, Centre des Maladies Endocrines Rares de la Croissance, Paris, France. ^[12] University of Modena and Reggio Emilia, Modena, Italy. ^[13] University Children's Hospital, Bochum, Germany. ^[14] Oregon Health and Science University, Portland, Oregon. ^[15] Hospital Vall d'Hebron, Universidad Autónoma de Barcelona, Barcelona, Spain. ^[16] Osaka City General Hospital, Miyakojima-ku, Osaka, Japan. ^[17] University of Giessen, Giessen, Germany. ^[18]